SILVERARC CAPITAL MANAGEMENT, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001816307

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q4 2024 · 60 positions · Total reported value $440.92M · Top-10 concentration 49.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 15 new · 20 cut · 18 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $855.33M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.7% · vs SPY -6.9% · Latest Value $784.53M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2024 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC disclosed 60 equity positions with a combined reported value of $440.92M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 49.3% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2024 were NUVL ($31.31M), MRUS ($28.63M), INSM ($25.70M). By sector, the heaviest allocations are Health Care 61.9%, Industrials 0.2%. Versus the prior quarter, allocation shifted toward Health Care (+2.4pp) and away from Other (-2.2pp).

Versus the prior quarter, SILVERARC CAPITAL MANAGEMENT, LLC opened 15 new positions, trimmed 20 and fully exited 18, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 57% of names.

The largest new positions opened in Q4 2024 were PLRX ($17.33M), SRRK ($7.92M), KROS ($6.12M).

Of the 18 positions fully exited versus the prior quarter, the largest were ALNY ($9.84M), PTGX ($6.60M), SRPT ($6.40M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • PLRX PLIANT THERAPEUTICS INC · $17.33M
  • SRRK SCHOLAR ROCK HLDG CORP · $7.92M
  • KROS KEROS THERAPEUTICS INC · $6.12M
  • RARE ULTRAGENYX PHARMACEUTICAL IN · $5.23M
  • TVTX TRAVERE THERAPEUTICS INC · $4.83M
  • INCY INCYTE CORP · $3.38M
  • VRDN VIRIDIAN THERAPEUTICS INC · $1.92M
  • DCTH DELCATH SYS INC · $1.87M

Fully Exited (vs previous quarter)

  • ALNY ALNYLAM PHARMACEUTICALS INC · prev qtr: $9.84M
  • PTGX PROTAGONIST THERAPEUTICS INC · prev qtr: $6.60M
  • SRPT SAREPTA THERAPEUTICS INC · prev qtr: $6.40M
  • ADCT ADC THERAPEUTICS SA · prev qtr: $5.65M
  • BHVN BIOHAVEN LTD · prev qtr: $4.98M
  • LBPH LONGBOARD PHARMACEUTICALS IN · prev qtr: $4.14M
  • BIIB BIOGEN INC · prev qtr: $3.87M · history
  • SLDB SOLID BIOSCIENCES INC · prev qtr: $3.19M · history

Insider Transactions (Form 4)

Latest SILVERARC CAPITAL MANAGEMENT, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Silverarc Capital Management is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 67 US equity positions with a combined value of $855.33M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-116845 (status: Approved), registered 2019-06-21
  • Regulatory AUM (Form ADV): $1.61B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: silverarccapital.com

Portfolio Structure

  • 67 positions · $855.33M reported value (Q2 2026)
  • Top 10 holdings = 47.1% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 6.4%
  • Average position size: $12.77M

Sector Tilt

  • Health Care 98.1%
  • Financials 1.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 19 new, 16 added, 28 reduced, 20 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 61.9%
Other 37.9%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 400.01K $31.31M 7.10%
7.10%
Add
2 680.85K $28.63M 6.49%
6.49%
Add
3 372.23K $25.70M 5.83%
5.83%
Add
4 516.01K $23.96M 5.43%
5.43%
Add
5 739.56K $20.57M 4.67%
4.67%
Add
6 503.28K $19.93M 4.52%
4.52%
Add
7 7.54M $18.94M 4.29%
4.29%
Add
8 1.32M $17.33M 3.93%
3.93%
New
9 543.65K $15.81M 3.59%
3.59%
Add
10 273.90K $15.33M 3.48%
3.48%
Add
11 179.09K $14.96M 3.39%
3.39%
Add
12 1.12M $11.93M 2.71%
2.71%
Add
13 598.95K $10.03M 2.27%
2.27%
Reduce
14 1.00M $9.95M 2.26%
2.26%
Add
15 1.01M $9.72M 2.20%
2.20%
Reduce
16 1.18M $9.51M 2.16%
2.16%
Add
17 3.07M $9.26M 2.10%
2.10%
Add
18 183.24K $7.92M 1.80%
1.80%
New
19 608.90K $7.53M 1.71%
1.71%
Reduce
20 921.14K $7.18M 1.63%
1.63%
Reduce
21 51.49K $7.09M 1.61%
1.61%
Add
22 110.38K $7.00M 1.59%
1.59%
Add
23 264.56K $6.69M 1.52%
1.52%
Add
24 1.78M $6.67M 1.51%
1.51%
Add
25 4.33M $6.63M 1.50%
1.50%
Add
26 220.00K $6.12M 1.39%
1.39%
New
27 6.17M $5.58M 1.27%
1.27%
Add
28 72.52K $5.58M 1.27%
1.27%
Add
29 513.37K $5.39M 1.22%
1.22%
Hold
30 124.39K $5.23M 1.19%
1.19%
New
31 612.17K $5.19M 1.18%
1.18%
Add
32 277.37K $4.83M 1.10%
1.10%
New
33 1.22M $4.40M 1.00%
1.00%
Add
34 152.40K $4.13M 0.94%
0.94%
Add
35 65.95K $3.65M 0.83%
0.83%
Add
36 49.00K $3.38M 0.77%
0.77%
New
37 40.79K $3.34M 0.76%
0.76%
Reduce
38 920.02K $3.26M 0.74%
0.74%
Reduce
39 734.23K $3.03M 0.69%
0.69%
Add
40 1.62M $2.49M 0.56%
0.56%
Add
41 1.59M $2.44M 0.55%
0.55%
Add
42 172.40K $2.28M 0.52%
0.52%
Reduce
43 285.12K $2.09M 0.47%
0.47%
Reduce
44 2.49M $1.97M 0.45%
0.45%
Reduce
45 100.00K $1.92M 0.43%
0.43%
New
46 155.32K $1.87M 0.42%
0.42%
New
47 100.00K $1.77M 0.40%
0.40%
New
48 1.27M $1.74M 0.40%
0.40%
Reduce
49 231.07K $1.60M 0.36%
0.36%
New
50 147.20K $1.56M 0.35%
0.35%
New

FAQ

What did SILVERARC CAPITAL MANAGEMENT, LLC buy in 2024-Q4?

In its 2024-Q4 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC reported 60 equity positions worth $440.92M in aggregate; its largest disclosed positions were NUVL ($31.31M), MRUS ($28.63M), INSM ($25.70M).

How large is SILVERARC CAPITAL MANAGEMENT, LLC's portfolio?

SILVERARC CAPITAL MANAGEMENT, LLC reported $440.92M of long equity holdings across 60 positions as of 2024-Q4. Top-10 holdings account for 49.3% of reported value.

What is SILVERARC CAPITAL MANAGEMENT, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/silverarc-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →